[ACCESSWIRE]
LAS VEGAS, NV / ACCESSWIRE / August 31, 2016 / Outside of the energy sector, the past year, there has not been any sector under more pressure than biotechnology. As an example of the bearish bias, the ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ: BIB) has slumped from a record high last July at $106.10 to a low of $33.97 late in June, representing a top-to-bottom decline of 68%. For the most part, biotechs of all sizes have felt the pain. Markets are always cyclical and I believe the biotech beat down is reaching its bottom and will soon begin to reverse the trend. From a technical perspective, I think that BIB breaking over $50 again will be a sign of the reversal (it's currently around $43).
With the recent drop in the value of Endonovo Therapeutics (ENDV), the company is worthy of additional due diligence. This company is working on the cutting edge of biotechnology in a field known as bioelectronics, which is the study and application of electronics in medicine and biological processes. It is a field that brings together engineering, materials science, nanotechnology, medicine and biology to explore and harness molecular and cellular processes under the control or influence of electrical signals. There are far reaching applications of these technologies from biosensors and the ability to control stem cells and biomolecules through electronic circuits to developing implantable and non-implantable devices that can control organ functions and lower inflammation. This is why GlaxoSmithKline is teaming up with Alphabet, Google's parent company, to form Galvani Bioelectronics in order to research, develop and commercialize the use of electrical signals to treat diseases. The companies will invest up to $715 million over 7 years to meet the goal of producing tiny implantable devices to treat diseases like arthritis, diabetes and asthma within a decade.
Endonovo is developing electronic devices to produce more potent stem cells and non-invasive electroceutical devices to treat inflammation in vital organs. One of Endonovo's lead programs is the Immunotronics platform, a non-invasive, non-implantable electroceutical device for treating and/or preventing vital organ failure resulting from an out of control immune response to infection or injury. The initial focus of the company is to use the Immunotronics platform to treat acute and chronic inflammatory conditions of the liver, such as acute liver injury, fulminant hepatic failure and Non-Alcoholic Steatohepatitis (NASH).
Here are a few highlights we believe make ENDV an extremely interesting company to watch to bounce with biotech:
- Endonovo's technology was shown to be a very potent non-invasive, anti-inflammatory device in a pre-clinical, pharmaceutical industry gold standard model of acute inflammation
- The Company just receive a patent covering the production of biologics, like G-CSF, GM-CSF, IL-2 and EPO using its novel bioreactors for growing stem cells
- ENDV just filed a patent application covering the use of biologics produced by its Cytotronics™ platform for the treatment of chemical and radiation injuries, like chemotherapy and exposure to radiation
- Immunotronics™ technology is completely non-invasive, whereas ENDV's competitors are largely pursuing invasive implantable devices
- Therapies target large unmet clinical needs in treating and preventing organ failure and other inflammatory conditions in vital organs
This week is a great time to consider taking a long look at ENDV.
After releasing financials and news last week, a few biotechs have been running:
Ocular Therapeutix, Inc. (OCUL) released its Q2 financials and has been on quite a run since, culminating in Monday's large price jump.
Lpath, Inc. (LPTN) just filed an S-3 registration statement to raise up to $10 million in equity financing to pursue strategic mergers or acquisitions. The stock has nearly double since last week and may have some room to run if LTPN announces a deal like STEM did the week before.
StemCells, Inc. (STEM) announced a strategic merger with Microbot Medical Ltd., an Israel-based developer of robotics-based medical devices and has since been an incredible run.
Eleven Biotherapeutics, Inc. (EBIO) investors reacted extremely favorably to EBIO's Q2 financials.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.
SOURCE: ACR Communication, LLC
